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Abstract.  It  is  generally  assumed  that  anticholinergic  drugs  have  no  effects  on 
schizophrenic  symptomatology.  A  few  studies,  however,  indicate  that  anti- 
cholinergic  agents  aggravate  psychotic  symptoms  and  antagonize  therapeutic 
effects of neuroleptics  in schizophrenic  patients;  more  recently,  some investigators 
have  observed  that  these  agents  appear  to benefit  negative  symptoms.  In an effort 
to resolve  this issue, we studied  the effects of 2 days  of treatment  with biperiden  on 
positive  and  negative  symptoms  in  15 medication-free  schizophrenic  patients. 
Positive  symptoms  increased  significantly,  while  there  was  a  trend  toward  a 
decrease  in  negative  symptoms.  The  implications  of these  findings  for the  role  of 
the  cholinergic  system  in  schizophrenia  are  discussed. 
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Anticholinergic  drugs  are  commonly  used  in  the  treatment  of  extrapyramidal  side 
effects,  which  frequently  accompany  neuroleptic  treatment  in  schizophrenia.  It  is 
assumed  that  anticholinergic  drugs  do not  affect  schizophrenic  symptomatology,  and 
general  clinical  experience  is consistent  with  this assumption.  There  were some early 
reports,  however,  of anticholinergic  drugs exacerbating  psychotic  symptomatology  in 
schizophrenic  patients  (Gershon  and Olariu,  1960; Itil et al., 1969). These  observations 
have  been  supported  by  several  recent  studies  showing  that  antimuscariniclanti- 
cholinergic  agents  may  antagonize  the  therapeutic  effects  of  neuroleptics  in schizo- 
phrenia  (Singh  and  Kay,  1979; Johnstone  et al.,  1983, 1988; Singh  et al.,  1987). The 
adverse  effects  of  anticholinergic  drugs  in schizophrenia  are  reportedly  confined  to 
positive  symptoms,  without  any  effects  on  negative  symptoms.  In fact,  some  recent 
studies  indicate  that  trihexiphenidyl,  an  antimuscarinic  agent,  may  actually  have 
beneficial  effects  on  negative  schizophrenic  symptoms  (Fayen  et al.,  1988; Tandon  et 
al.,  1988). 
In view of the frequent  use of anticholinergic  agents  in schizophrenia,  the dearth  of 
controlled  studies  on  the  effects  of  anticholinergic  drugs  on  symptomatology  in 
medication-free  schizophrenic  patients  is surprising.  In this  study,  we examined  the 
effects  of biperiden,  a relatively  specific  M, antimuscarinic/anticholinergic  agent,  on 
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positive  and  negative  symptoms  in  15 schizophrenic  inpatients  who  were  otherwise 
free  of  medication. 
Methods 
Patients  and  Study  Design.  The  sample  consisted  of  15 consecutively  hospitalized  patients 
who  were  admitted  to  the  Schizophrenia  Inpatient  Program  at  the  University  of  Michigan. 
Diagnostic  evaluation  included  a  structured  interview  using  the  Schedule  for  Affective  Dis- 
orders  and  Schizophrenia  (SADS;  Endicott  and  Spitzer,  1978),  as  well  as  all  available  history 
and  clinical  observations.  Patients  had  to meet  both  DSM-III-R  criteria(American  Psychiatric 
Association,  1987) and  Research  Diagnostic  Criteria(RDC;  Spitzeret  al.,  1978) for  inclusion  in 
the  study.  The  sample  consisted  of  11 men  and  4 women  with  a mean  age  of 29 (SD  = 6) years  and 
a mean  duration  of  illness  of  6 (SD  q 4) years.  All  of  the  patients  were  free  of medical  disorders. 
None  of  them  had  received  depot  neuroleptics  for  at  least  6 months  before  entering  the  study. 
After  having  been  maintained  in a medication-free  state  for  at  least  2 weeks,  patients  received 
4 mg  of  biperiden  on  night  1, two  doses  of 4 mg  biperiden  the  next  day,  and  a 4 mg  morning  dose 
of  biperiden  on  day  3. Two  nurse-clinician  raters  (N.A.M.  and  W.H.E.),  without  knowledge  of 
patients’  medication  status  and  the  rationale  of  the  study,  independently  rated  the  patients  on 
the  18-item  Brief  Psychiatric  Rating  Scale  (BPRS;  Overall  and  Gorham,  1962) before  starting 
biperiden  on  day  1  (baseline)  and  day  3 (postbiperiden).  Scores  on  BPRS  items  assessing  motor 
retardation,  blunted  affect,  and  emotional  withdrawal  (rated  1 for  not  present  to  7 for  severe) 
were  summed  and  used  as  the  BPRS  negative  symptom  cluster.  These  items  collectively 
constitute  the  “ANER”  factor  (Guy,  1976;  Hedlund  and  Viewig,  1980).  The  BPRS  items 
assessing  conceptual  disorganization,  suspiciousness,  hallucinatory  behavior,  and  unusual 
thought  content  were  summed  as  the  BPRS  positive  symptom  cluster.  The  BPRS  was  used  to 
rate  positive  and  negative  symptomatology  because  it  is  a  reliable,  sensitive,  and  effective 
measure  of  psychopathology  and  of  treatment-related  symptom  changes  (Hedlund  and  Viewig, 
1980). 
Biperiden  was  used  as  the  antimuscarinic/anticholinergic  agent  because,  as  a  relatively 
specific  M,  antimuscarinic  antagonist  (Syvalalrti  et  al.,  1987;  Eltze  and  Figala,  1988)  it causes 
significantly  fewer  peripheral  anticholinergic  side  effects  than  other  commonly  used  oral 
anticholinergic  agents  and  is better  tolerated  (Avissar  and  Schreiber,  1989).  Furthermore,  M, 
receptors  are  located  in  the  brain  areas  considered  relevant  in  schizophrenia  (Bonner  et  al., 
1987;  Watson  et  al.,  1987)  and  are  thus  the  receptor  system  most  likely  to  be  implicated  in 
schizophrenic  symptomatology.  Since  the  usual  daily  dosage  of  biperiden  in  the  treatment  of 
parkinsonian  symptoms  is 4-12  mg/day,  we  elected  to  use  8 mg  in two  divided  doses.  The  3-day 
duration  of  the  study  was  selected  because  (1) the  effect  of a single  dose  on  symptomatology  may 
be  limited  by  the  inability  of  the  system  to  respond  this  quickly  to  anticholinergic  modulation; 
and  (2)  compensatory  changes  to  the  initial  primary  effect  of  biperiden  might  occur  over  a 
longer  period,  thereby  interfering  with  the  evaluation  of  the  primary  effect. 
Data  Analysis.  Paired  two-tailed  r  tests  were  performed  to  compare  the  symptom  ratings  at 
baseline  to  those  in  the  postbiperiden  phase. 
Results 
The  BPRS  total  scores  at  baseline  ranged  from  35  to  72 (mean  = 48.2,  SD  = 12.3).  In 
this  study,  interrater  reliability  coefficients  (measured  by  the  Pearson  product- 
moment  correlations)  between  the  two  independent  raters  (N.A.M.  and  W.H.E.)  for 
the  18 individual  BPRS  items  ranged  from  0.70  to  0.95,  with  a  median  of  0.85.  The 
interrater  reliability  coefficients  for  the  positive  and  negative  symptom  clusters  were 
0.92  and  0.87,  respectively. 
Baseline  positive  symptom  cluster  scores  ranged  from  7 to  20  (mean  = 12.8,  SD  = 237 
3.6).  There  was  a significant  increase  inpositivesymprom  severity  following  biperiden 
(t = 4.4,  df=  14,~  <  O.Ol),  with  postbiperiden  positive  symptom  cluster  scores  ranging 
from  6 to  22  (mean  q  15.7,  SD  = 4.4).  (See  Fig.  1.) 
Baseline  negative  symptom  cluster  scores  ranged  from  3.5 to  16.5 (mean  = 9.0,  SD  = 
3.7).  There  was  a  trend  toward  a  decrease  in  negative  symptom  severity  following 
biperiden  (t  = -1.9,  df=  14, p  = 0.08),  with  postbiperiden  negative  symptom  cluster 
scores  ranging  from  4  to  14  (mean  =  7.9,  SD  =  3.0).  (See  Fig.  1.)  There  was  no 
association  between  changes  in  positive  and  negative  symptom  severity  (r = 0.27,  n = 
15,  NS). 
Daily  monitoring  of  patients’  clinical  status  by  their  respective  primary  nurses 
(different  from  the  nurse-clinician  raters)  was  consistent  with  the  changes  in  positive 
and  negative  symptoms  noted  on  the  BPRS.  After  biperiden,  patients  were  reported  as 
being  more  “open,”  expressive,  engaging,  and  communicative.  The  primary  nurses 
also  noted  an  increased  reporting  of  positive  symptomatology  (e.g.,  delusions  and 
hallucinations)  by  the  patients,  which  they  ascribed  to  their  increased  “openness”  and 
expressiveness, 
Fig.  1. Change  in positive and negative symptoms  following  biperiden in 
schizophrenic patients (n  =  15) 
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Discussion 
The  finding  that  the  severity  of  positive  symptoms  increases  following  the  administra- 
tion  of biperiden  to  medication-free  schizophrenic  patients  is consistent  with  previous 
reports  of aggravation  of psychotic  symptomatology  (Gershon  and  Olariu,  1960;  Itil  et 
al.,  1969)  and  antagonism  of  the  therapeutic  effects  of  neuroleptics  on  positive 
symptoms  (Haase,  1965;  Singh  and  Kay,  1979;  Johnstone  et al.,  1983,  1988;  Singh  et 
al.,  1987)  in  schizophrenic  patients  by  anticholinergic  agents.  On  the  other  hand, 
several  studies  have  demonstrated  that  abrupt  or  gradual  withdrawal  of  anti- 
cholinergic  drugs  has  no  salutary  effect  on  schizophrenic  symptoms  and,  in  fact,  may 
occasionally  be  associated  with  a  worsening  of  the  clinical  state  (Ananth  et al.,  1970; 
McClelland  et al.,  1974;  Rifkin  et al.,  1975;  Jellinek  et al.,  1981; Manos  et al.,  1981).  A 
review  of  the  literature  reveals  that  studies  showing  no  adverse  effects  of  anti- 
cholinergic  drugs  and  no  improvement  following  anticholinergic  withdrawal  in 
schizophrenic  patients  were  conducted  in  the  chronic  neuroleptic-stabilized  phase  of 
the  illness,  while  investigations  documenting  adverse  effects  of  anticholinergic  drugs 
on  positive  symptoms  were  conducted  in  the  acute  phase  of  the  illness.  In  any  event, 
virtually  all  these  studies  were  conducted  in  schizophrenic  patients  receiving  neuro- 
leptics,  and  any  effect  of reducing  cholinergic  activity  could  have  been  obscured  by the 
simultaneously  decreased  dopaminergic  activity  due  to  the  neuroleptic.  In  the  present 
study,  the  effects  of  biperiden  were  evaluated  in  otherwise  medication-free  patients, 
thereby  eliminating  the  “confounding”  effect  of  neuroleptic  medication.  The  impor- 
tance  of  disturbances  in  dopaminergic/cholinergic  balance  in  the  expression  of posi- 
tive  schizophrenic  symptoms  is  supported  by  the  finding  that  the  exacerbation  in 
positive  symptoms  produced  by  methylphenidate  (an  agent  that  enhances  dopamine 
neurotransmission)  in  schizophrenic  patients  is reversed  by  physostigmine  (an  agent 
that  enhances  cholinergic  neurotransmission)  (Janowsky  et  al.,  1973). 
While  positive  symptoms  increased  following  biperiden,  negative  symptoms 
showed  a  tendency  to  decrease.  The  observed  reduction  in  negative  symptoms  with 
biperiden  is  consistent  with  previous  reports  of  beneficial  effects  of  anticholinergic 
agents  on  negative  schizophrenic  symptoms  (Fayen  et al.,  1988;  Tandon  et  al.,  1988). 
In  these  earlier  studies,  however,  patients  were  also  receiving  neuroleptic  drugs, 
raising  the  possibility  that  the  beneficial  effects  of  the  anticholinergic  agents  were 
related  to  relief  of  akinesia,  despite  the  absence  of  any  overt  extrapyramidal  side 
effects.  The  present  study,  in  which  patients  were  medication  free  except  for  the  “study 
drug”  biperiden,  makes  that  interpretation  less  likely. 
In  view  of the  covariance  of positive  and  negative  symptoms  in  the  psychotic  phase 
of schizophrenia  and  their  concomitant  response  to  neuroleptic  treatment  (Goldberg, 
1985;  Breier  et  al.,  1987;  van  Kammen  et  al.,  1987;  Goldman  and  Tandon,  1989;  Kay 
and  Singh,  1989;  Keefe  et al.,  1989),  our  findings  of an  increase  in  positive  symptoms 
and  a  decrease  in  negative  symptoms  following  a  reduction  in  cholinergic  activity 
(with  biperiden)  appear  puzzling.  They  are,  however,  consistent  with  and  predictable 
from  the  recently  proposed  model  of dopaminergic/  cholinergic  interactions  in schizo- 
phrenia  (Tandon  and  Greden,  1989,  in  press).  This  model  suggests  that  (1) cholinergic- 
dopaminergic  balance  is  of central  importance  in  schizophrenic  pathophysiology;  (2) 
muscarinic  activity  increases  in  an  attempt  to  maintain  this  balance  in  the  face  of 239 
increasing  dopaminergic  activity  that  occurs  in  the  psychotic  phase  of  the  illness;  (3) 
the  muscarinic/cholinergic  system  exerts  a  damping  effect  on  the  emergence  of 
positive  symptoms  associated  with  dopaminergic  hyperactivity;  and  (4) this  compen- 
satory  increase  in  muscarinic  activity  is in  turn  accompanied  by  an  intensification  of 
negative  symptoms  during  and  following  the  psychotic  phase  of  the  illness. 
Reducing  cholinergic  activity  without  concomitantly  decreasing  dopaminergic 
activity  (as  in  the  present  study)  would  be  expected  to  increase  positive  symptoms,  as 
the  cholinergic  system  may  afford  protection  against  the  emergence  of positive  symp- 
toms  associated  with  dopaminergic  hyperactivity.  At  the  same  time,  decreasing  choli- 
nergic  activity  would  be  expected  to  result  in a reduction  of negative  symptoms  (as the 
“compensatory”  cholinergic  hyperactivity  is implicated  as  a  major  mechanism  in  the 
production  of negative  symptoms  at  this  phase  of the  illness).  On  the  other  hand,  both 
positive  and  negative  symptoms  would  be  expected  to  improve  with  neuroleptic 
treatment.  As  dopaminergic  activity  decreases  with  neuroleptic  treatment  (and  posi- 
tive  symptoms  improve),  there  should  be  a  corresponding  reduction  in  muscarinic 
activity,  since  an  increase  in  muscarinic  activity  presumably  occurred  as a “compensa- 
tory”  response  to  the  increased  dopaminergic  activity  in  this  phase  of the  illness.  This 
reduction  in  muscarinic/  cholinergic  activity  would  be  accompanied  by  an  improve- 
ment  in  negative  symptoms. 
Several  methodological  issues  deserve  comment:  (1) Anticholinergic  drugs,  particu- 
larly  benztropine,  may  cause  dopamine  release  and  block  reuptake  (thereby  increasing 
central  dopaminergic  activity)  (Horn  et  al.,  1971;  Model1  et  al,  1989).  Thus,  the 
increase  in  positive  symptoms  and  the  decrease  in  negative  symptoms  with  biperiden 
could  possibly  be ascribed  to its dopaminergic  rather  than  its anticholinergic  property. 
Commonly  used  anticholinergic  drugs  other  than  benztropine,  however,  have  very 
weak  effects  on  the  dopamine  and  other  catecholamine  receptors,  and  biperiden  has 
the  least  potent  activity  in  this  regard  (Horn  et  al.,  197 1). While  it is therefore  unlikely 
that  the  observed  effects  of biperiden  on  positive  and  negative  symptoms  are  related  to 
its  insignificant  dopaminergic  activity,  this  alternative  explanation  cannot  be  com- 
pletely  dismissed.  (2)  While  the  increase  in  positive  symptoms  that  occurred  with 
biperiden  was  very  highly  significant,  the  decrease  in  negative  symptoms  only  showed 
a  trend  toward  significance  (JJ = 0.08).  Whether  this  reflects  the  need  for  a  larger 
sample,  limitations  of our  instruments,  or absence  of a real  effect  needs  to  be evaluated 
in  future  studies.  Even  if  these  effects  of  an  anticholinergic  agent  on  positive  and 
negative  symptoms  were  confirmed,  the  clinical  relevance  of  such  findings  would 
require  further  evaluation.  (3)  These  findings  must  be  considered  preliminary  and 
require  corroboration  in  larger  samples  with  a  placebo-controlled  design. 
If  these  findings  are  confirmed,  they  have  important  pathophysiological  implica- 
tions  for  the  role  of  the  cholinergic  system  in  schizophrenia.  They  may  also  have 
implications  for  therapy  in  view  of (1) the  widespread  use  of anticholinergic  agents  in 
the  treatment  of extrapyramidal  side  effects  of neuroleptics  and  (2) the  fact  that  many 
neuroleptic  drugs  also  have  potent  anticholinergic  effects. 
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